dapagliflozin has been researched along with Diabetic-Nephropathies* in 1 studies
1 other study(ies) available for dapagliflozin and Diabetic-Nephropathies
| Article | Year |
|---|---|
Novel C-aryl glucoside SGLT2 inhibitors as potential antidiabetic agents: 1,3,4-Thiadiazolylmethylphenyl glucoside congeners.
Novel C-aryl glucoside SGLT2 inhibitors containing 1,3,4-thiadiazole moieties were designed and synthesized. Among the compounds tested, biaryl-type compounds containing pyrazine 59, 2-furan 61, and 3-thiophene 71 showed the best in vitro inhibitory activities to date (IC(50) = 3.51-7.03 nM) against SGLT2. A selected compound 61, demonstrated reasonable blood glucose-lowering effects, indicating that the information obtained from the SAR studies in this 1,3,4-thiadiazolylmethylphenyl glucoside series might help to design more active SGLT2 inhibitors that are structurally related. Topics: Animals; Diabetic Nephropathies; Drug Design; Glucosides; Humans; Hypoglycemic Agents; Male; Mice; Mice, Inbred Strains; Molecular Structure; Rats; Rats, Sprague-Dawley; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Stereoisomerism; Structure-Activity Relationship; Thiadiazoles | 2010 |